Suppr超能文献

急性视网膜坏死。治疗与视觉预后:病例系列

Acute retinal necrosis. Management and visual outcomes: a case series.

作者信息

Mojarrad Alireza, Omidtabrizi Arash, Ansari Astaneh Mohammadreza, Bakhtiari Elham, Shiezadeh Elham, Hassani Mohadeseh, Hosseini Seyedeh Maryam

机构信息

Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Retina Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

出版信息

Int J Retina Vitreous. 2022 Sep 15;8(1):66. doi: 10.1186/s40942-022-00417-w.

Abstract

BACKGROUND

The present study reports the functional and anatomical outcomes of eyes with acute retinal necrosis(ARN).

METHODS

This is a retrospective case series conducted at a tertiary Eye Hospital from March 2015 to March 2020. Medical records of patients with clinical and laboratorial-Polymerase Chain Reaction (PCR)-diagnosis of ARN were reviewed. To identify factors related to the outcomes of visual acuity(VA) and retinal detachment (RD) over time, Cox proportional hazards regression modeling and survival analyses were used.

RESULTS

Twenty-three eyes of 23 patients (16 male, 7 female) were reviewed. Based on the PCR results, 16 cases (69.6%) had Varicella zoster virus, 3 cases (13%) had Cytomegalovirus, 1 patient (4.3%) had Herpes simplex virus associated ARN, and 1 case (4.3%) had negative PCR. The incident rate for ≥ 2-line VA gain was 0.28/eye-year (EY) (95% CI 0.21 ± 0.26) while the rate of severe vision loss was 0.09/eye-year (95% CI 0.05 ± 0.08). The RD development was observed at a rate of 0.43/eye-year (0.42 ± 0.02), which occurred in 9 eyes with a mean time of 100 days after the initial presentation of ARN. Patients' age was the only factor associated with 2-line or more gain in VA over time with a hazard ratio of 0.921 (95% CI 0.854-0.993, P = 0.032).

CONCLUSIONS

Generally, although being crucial, treatment is not highly effective in improvement of VA and decrease of RD development, as well as vision loss, in patients with ARN. However, treatment prevents fellow eye involvement efficiently. Younger age is associated with better response to treatment and more chance to achieve better VA.

摘要

背景

本研究报告了急性视网膜坏死(ARN)患者眼部的功能和解剖学转归。

方法

这是一项于2015年3月至2020年3月在一家三级眼科医院开展的回顾性病例系列研究。对临床及实验室聚合酶链反应(PCR)诊断为ARN的患者病历进行了回顾。为确定随时间推移与视力(VA)和视网膜脱离(RD)转归相关的因素,采用了Cox比例风险回归模型和生存分析。

结果

对23例患者(16例男性,7例女性)的23只眼进行了回顾。根据PCR结果,16例(69.6%)为水痘带状疱疹病毒感染,3例(13%)为巨细胞病毒感染,1例(4.3%)为单纯疱疹病毒相关性ARN,1例(4.3%)PCR结果为阴性。视力提高≥2行的发生率为0.28/眼年(EY)(95%CI 0.21±0.26),而严重视力丧失的发生率为0.09/眼年(95%CI 0.05±0.08)。RD的发生速率为0.43/眼年(0.42±0.02),9只眼中出现RD,平均发生时间为ARN初次就诊后100天。患者年龄是随时间推移视力提高2行或更多的唯一相关因素,风险比为0.921(95%CI 0.854 - 0.993,P = 0.032)。

结论

总体而言,尽管治疗至关重要,但在改善ARN患者的视力、降低RD发生率以及预防视力丧失方面效果并不显著。然而,治疗能有效预防健眼受累。年龄较小的患者对治疗反应更好,获得较好视力的机会更大。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8211/9476592/c7e5af26a36d/40942_2022_417_Fig1_HTML.jpg

相似文献

1
Acute retinal necrosis. Management and visual outcomes: a case series.
Int J Retina Vitreous. 2022 Sep 15;8(1):66. doi: 10.1186/s40942-022-00417-w.
2
Outcomes of Combination Systemic and Intravitreal Antiviral Therapy for Acute Retinal Necrosis.
Ophthalmol Retina. 2021 Mar;5(3):292-300. doi: 10.1016/j.oret.2020.07.012. Epub 2020 Jul 16.
3
Risk Factors for Retinal Detachment in Acute Retinal Necrosis.
Ophthalmol Retina. 2022 Jun;6(6):478-483. doi: 10.1016/j.oret.2022.01.016. Epub 2022 Feb 1.
4
Acute Retinal Necrosis: Presenting Characteristics and Clinical Outcomes in a Cohort of Polymerase Chain Reaction-Positive Patients.
Am J Ophthalmol. 2017 Jul;179:179-189. doi: 10.1016/j.ajo.2017.05.006. Epub 2017 May 10.
5
Acute retinal necrosis features, management, and outcomes.
Ophthalmology. 2007 Apr;114(4):756-62. doi: 10.1016/j.ophtha.2006.08.037. Epub 2006 Dec 20.
6
Acute retinal necrosis: clinical features, management and outcomes.
Int Ophthalmol. 2023 Jun;43(6):1987-1994. doi: 10.1007/s10792-022-02598-7. Epub 2022 Nov 27.
7
Acute retinal necrosis: the effects of intravitreal foscarnet and virus type on outcome.
Ophthalmology. 2010 Mar;117(3):556-60. doi: 10.1016/j.ophtha.2009.08.003. Epub 2009 Dec 23.
8
Acute retinal necrosis: Clinical manifestation and long-term visual outcomes in a series of polymerase chain reaction-positive patients.
Eur J Ophthalmol. 2021 Jul;31(4):1961-1969. doi: 10.1177/1120672120936181. Epub 2020 Jun 21.
9
A case of Epstein-Barr virus acute retinal necrosis successfully treated with foscarnet.
Am J Ophthalmol Case Rep. 2022 Jan 29;25:101363. doi: 10.1016/j.ajoc.2022.101363. eCollection 2022 Mar.

引用本文的文献

1
Eye on cytomegalovirus: Unveiling the ophthalmic impact of cytomegalovirus.
World J Virol. 2025 Jun 25;14(2):101944. doi: 10.5501/wjv.v14.i2.101944.
2
Clinical profile and treatment outcomes in acute retinal necrosis in a South Indian patient population.
Indian J Ophthalmol. 2025 Jun 1;73(6):858-863. doi: 10.4103/IJO.IJO_1585_24. Epub 2025 Apr 17.
4
Analysis of prognostic factors in acute retinal necrosis using ultrawide-field fundus imaging.
Graefes Arch Clin Exp Ophthalmol. 2025 Mar 4. doi: 10.1007/s00417-025-06789-7.
7
Clinical Spectrum and Perspective in Bilateral Acute Retinal Necrosis: Systematic Review.
Medicina (Kaunas). 2024 Oct 23;60(11):1735. doi: 10.3390/medicina60111735.
8
9
Acute retinal necrosis in a patient with cervical malignant tumor treated with sintilimab: a case report and literature review.
Front Immunol. 2024 Jan 23;15:1301329. doi: 10.3389/fimmu.2024.1301329. eCollection 2024.

本文引用的文献

1
Management Strategies of Acute Retinal Necrosis: Current Perspectives.
Clin Ophthalmol. 2020 Jul 8;14:1931-1943. doi: 10.2147/OPTH.S258488. eCollection 2020.
2
Outcomes of Combination Systemic and Intravitreal Antiviral Therapy for Acute Retinal Necrosis.
Ophthalmol Retina. 2021 Mar;5(3):292-300. doi: 10.1016/j.oret.2020.07.012. Epub 2020 Jul 16.
3
Acute retinal necrosis: Clinical manifestation and long-term visual outcomes in a series of polymerase chain reaction-positive patients.
Eur J Ophthalmol. 2021 Jul;31(4):1961-1969. doi: 10.1177/1120672120936181. Epub 2020 Jun 21.
4
BILATERAL ACUTE RETINAL NECROSIS: A Case Series.
Retina. 2020 Jan;40(1):145-153. doi: 10.1097/IAE.0000000000002341.
5
Bilateral Acute Retinal Necrosis: Clinical Features and Outcomes in a Multicenter Study.
Ocul Immunol Inflamm. 2019;27(7):1090-1098. doi: 10.1080/09273948.2018.1501494. Epub 2018 Jul 30.
6
7
Comparing Treatment of Acute Retinal Necrosis With Either Oral Valacyclovir or Intravenous Acyclovir.
Am J Ophthalmol. 2018 Apr;188:173-180. doi: 10.1016/j.ajo.2018.02.001. Epub 2018 Feb 12.
8
Aflibercept in the management of acute retinal necrosis syndrome-related macular edema.
Eur J Ophthalmol. 2018 Mar;28(2):259-261. doi: 10.5301/ejo.5001039. Epub 2017 Sep 14.
9
Acute Retinal Necrosis: Presenting Characteristics and Clinical Outcomes in a Cohort of Polymerase Chain Reaction-Positive Patients.
Am J Ophthalmol. 2017 Jul;179:179-189. doi: 10.1016/j.ajo.2017.05.006. Epub 2017 May 10.
10
Diagnosis and Treatment of Acute Retinal Necrosis: A Report by the American Academy of Ophthalmology.
Ophthalmology. 2017 Mar;124(3):382-392. doi: 10.1016/j.ophtha.2016.11.007. Epub 2017 Jan 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验